Integrative therapy of traditional Chinese medicine and conventional medicine in the treatment of lupus nephritis from a single‐center experience

Abstract

Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus and the leading cause of mortality. The complex pathogenesis and various clinical manifestations of this disease increase the difficulty of the treatments. The current treatments with Western medicine including glucocorticoids, mycophenolate mofetil and other immunosuppressants, and biological agents have greatly improved the patients' survival. However, frequent recurrence occurred and LN remained an important cause of end stage renal disease. The increasing adverse effects with the prolongation of treatment also restrained the efficacy of Western medicine. Increasing evidence has demonstrated the therapeutic efficacy of traditional Chinese medicine (TCM) which provides a theoretical basis for the integrative therapy of TCM and Western medicine for LN. We previously established a unique comprehensive treatment strategy for LN with the combination of TCM and Western medicine based on the TCM theory and achieved good clinical efficacy. This review will summarize the single‐center experience that integrative therapy of TCM, represented by Lupus Recipe and artesunate, and Western medicine for LN treatment, and elucidate the potential mechanism, with the purpose to provide reliable evidence for developing more effective personalized treatment strategies in the future.

Keywords

artesunate / integrative therapy / lupus nephritis / lupus recipe / traditional Chinese medicine

References

[1] Parikh SV , Almaani S , Brodsky S , Rovin BH . Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020; 76 (2): 265- 281.

[2] Yung S , Chan TM . Anti-dsDNA antibodies and resident renal cells-their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin Immunol. 2017; 185: 40- 50.

[3] Crow MK . Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023; 82 (8): 999- 1014.

[4] Yung S , Ng CY , Au KY , et al. Binding of anti-dsDNA antibodies to proximal tubular epithelial cells contributes to renal tubulointerstitial inflammation. Clin Sci (Lond). 2017; 131 (1): 49- 67.

[5] Yung S , Ng CY , Ho SK , et al. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J Autoimmun. 2015; 58: 111- 122.

[6] Yung S , Cheung KF , Zhang Q , Chan TM . Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol. 2010; 21 (11): 1912- 1927.

[7] Alforaih N , Whittall-Garcia L , Touma Z . A review of lupus nephritis. J Appl Lab Med. 2022; 7 (6): 1450- 1467.

[8] Fanouriakis A , Kostopoulou M , Cheema K , et al. 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79 (6): 713- 723.

[9] Hocaoǧlu M , Valenzuela-Almada MO , Dabit JY , et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the lupus midwest network. Arthritis Rheumatol. 2023; 75 (4): 567- 573.

[10] Sciascia S , Mompean E , Radin M , Roccatello D , Cuadrado MJ . Rate of adverse effects of medium-to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Invest. 2017; 37 (6): 519- 524.

[11] Gomez Mendez LM , Cascino MD , Garg J , et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018; 13 (10): 1502- 1509.

[12] Melander C , Sallée M , Trolliet P , et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009; 4 (3): 579- 587.

[13] Davies RJ , Sangle SR , Jordan NP , et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013; 22 (6): 574- 582.

[14] Furie RA , Aroca G , Cascino MD , et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022; 81 (1): 100- 107.

[15] Yu C , Li P , Dang X , Zhang X , Mao Y , Chen X . Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022; 132: 102871.

[16] Heng M , Tu J , Hao Y , et al. Effects of integrated traditional Chinese and western medicine for the treatment of lupus nephritis: a meta-analysis of randomized trials. Evid Based Complement Alternat Med. 2016; 2016: 1502107.

[17] Wang XQ , Wang L , Tu YC , Zhang YC . Traditional Chinese medicine for refractory nephrotic syndrome: strategies and promising treatments. Evid Based Complement Alternat Med. 2018; 2018: 8746349- 8746411.

[18] Zhuang GK , Yuan ZZ , Zhang ZL , et al. Treatment of lupus erythematosus with integrated traditional Chinese Medicine and Western medicine. Chinese Journal of Integrated Traditional and Western Medicine. 1992; 12: 199- 202 (in Chinese).

[19] Yuan ZZ , Feng JC . Observation on the treatment of systemic lupus erythematous with a Gentiana macrophylla complex tablet and a minimal dose of prednisone. Chinese Journal of Modern Developments in Traditional Medicine. 1989; 9 (in Chinese).

[20] Ye RG , Ren GH , Li HQ . Therapy of integrated traditional Chinese Medicine and Western medicine on 74 lupus nephritis. Chinese Journal of Integrated Traditional and Western Medicine. 1994; 14 (in Chinese).

[21] Wu Q , Ye R , Wu K . Clinical observation on nephrotic syndrome of lupus nephritis treated with integrated traditional Chinese and Western Medicine. Chinese Journal of Integrated Traditional and Western Medicine. 1998; 18: 718- 720 (in Chinese).

[22] Shi YJ , Liu Y , Liu GX . Integrated Chinese and western medicinal treatment on systemic lupus erythematosus characterized by hypoplastic bone marrow. Chinese Journal of Integrated Traditional and Western Medicine. 2007; 27: 415- 417 (in Chinese).

[23] Yang X , Ye R , Pei C , et al. Observational study of Lang Chuang Fang and immunosuppressants in the treatment of lupus nephritis. Chin J Med. 2000; 35: 45- 46.

[24] Li W , Li H , Zhang M , et al. Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. Am J Physiol Ren Physiol. 2016; 311 (1): F217- F226.

[25] Li D , Shi G , Wang J , et al. Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells. Arthritis Res Ther. 2019; 21 (1): 105.

[26] Yan Y , Zhang Z , Chen Y , et al. Coptisine alleviates pristane-induced lupus-like disease and associated kidney and cardiovascular complications in mice. Front Pharmacol. 2020; 11: 929.

[27] Yang X , Ye R , Liu G , et al. The clinic and experimental researches on treatment of nephritic diseases with the integrating traditional Chinese medicine and western medicine for 38 years. Acad J SUMS. 2000; 21: 401- 408.

[28] Liu R , Huang X , Ye H , et al. Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy. Immun Inflamm Dis. 2023; 11 (3): e815.

[29] Yang X , Wei Y , Ye R , et al. Observation of lupus Recipe in treating lupus nephritis mice with chronic graft versus host disease. Chinese Journal of Integrated Traditional and Western Medicine. 2005; S1: 74- 77 (in Chinese).

[30] Huang KP , Zhang ZH , Li RM , Chen X . The therapeutic effects of the Chinese herbal medicine, lang chuang fang granule, on lupus-prone MRL/lpr mice. Evid Based Complement Alternat Med. 2016; 2016: 8562528.

[31] Zhang Y , Yang X , Chen W , et al. Effect of lupus Recipe contained serum on the expression of PPARγ and TNFα with IFNγ induced CD40 and RANTES on renal tubular epithelial cells. Chin J Exp Tradit Med Formulae. 2008; 14: 29- 33.

[32] Zhang YJ , Yang X , Kong QY , et al. Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). Am J Nephrol. 2006; 26 (4): 356- 362.

[33] Xu L , Li Y , Ji J , et al. The anti-inflammatory effects of Hedyotis diffusa Willd on SLE with STAT3 as a key target. J Ethnopharmacol. 2022; 298: 115597.

[34] Li Y , Ding T , Chen J , et al. The protective capability of Hedyotis diffusa Willd on lupus nephritis by attenuating the IL-17 expression in MRL/lpr mice. Front Immunol. 2022; 13: 943827.

[35] Lai Y , Ji J , Li Y , et al. Ethyl acetate fraction in Hedyotis diffusa Willd inhibits T cell proliferation to improve the pathogenesis of systemic lupus erythematosus. Clin Compl Med Pharmacol. 2021; 1: 100011.

[36] Ji L , Hou X , Deng X , et al. Jieduquyuziyin prescription-treated rat serum suppresses activation of peritoneal macrophages in MRL/lpr lupus mice by inhibiting IRAK1 signaling pathway. Evid Based Complement Alternat Med. 2019; 2019: 2357217- 2357313.

[37] Xu X , Chen F , Zhang L , et al. Exploring the mechanisms of anti-ovarian cancer of Hedyotis diffusa Willd and Scutellaria barbata D. Don through focal adhesion pathway. J Ethnopharmacol. 2021; 279: 114343.

[38] Dos Santos M , Poletti PT , Favero G , et al. Protective effects of quercetin treatment in a pristane-induced mouse model of lupus nephritis. Autoimmunity. 2018; 51 (2): 69- 80.

[39] Meshnick SR . Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002; 32 (13): 1655- 1660.

[40] Wang YJ , Li YX , Li S , et al. Progress in traditional Chinese Medicine and natural extracts for the treatment of lupus nephritis. Biomed Pharmacother. 2022; 149: 112799.

[41] Dhorda M , Amaratunga C , Dondorp AM . Artemisinin and multidrug-resistant Plasmodium falciparum-a threat for malaria control and elimination. Curr Opin Infect Dis. 2021; 34 (5): 432- 439.

[42] Talman AM , Clain J , Duval R , Ménard R , Ariey F . Artemisinin bioactivity and resistance in malaria parasites. Trends Parasitol. 2019; 35 (12): 953- 963.

[43] Li Y , Zhou X , Liu J , Yuan X , He Q . Therapeutic potentials and mechanisms of artemisinin and its derivatives for tumorigenesis and metastasis. Anti Cancer Agents Med Chem. 2020; 20 (5): 520- 535.

[44] Qiu F , Liu J , Mo X , Liu H , Chen Y , Dai Z . Immunoregulation by artemisinin and its derivatives: a new role for old antimalarial drugs. Front Immunol. 2021; 12: 751772.

[45] Shakir L , Hussain M , Javeed A , Ashraf M , Riaz A . Artemisinins and immune system. Eur J Pharmacol. 2011; 668 (1-2): 6- 14.

[46] Wu X , Zhang W , Shi X , An P , Sun W , Wang Z . Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin. 2010; 42 (12): 916- 923.

[47] Liang N , Zhong Y , Zhou J , et al. Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-κB signaling pathway in lupus nephritis mice. Exp Ther Med. 2018; 15: 2436- 2442.

[48] Wu XL , Zhang WG , Shi XM , et al. Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice. Chin J Integr Med. 2011; 17 (4): 277- 282.

[49] Jin Q , Liu T , Chen D , et al. Therapeutic potential of artemisinin and its derivatives in managing kidney diseases. Front Pharmacol. 2023; 14: 1097206.

[50] Jin O , Zhang H , Gu Z , et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol. 2009; 6: 461- 467.

[51] Dang WZ , Li H , Jiang B , et al. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway. Phytomedicine. 2019; 62: 152965.

[52] Wu Y , He S , Bai B , et al. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. Cell Mol Immunol. 2016; 13 (3): 379- 390.

[53] Lin Z , Liu Y , Chen L , et al. Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets. Sci China Life Sci. 2021; 64 (10): 1702- 1719.

[54] Yu J , Chen W , Fan L , et al. WCN23-1043 randomized, double-blind, controlled trial of artesunate in patients with active lupus nephritis. Kidney Int Rep. 2023; 8 (3): S473.

[55] Tanaka H , Akama H , Ichikawa Y , et al. Glucocorticoid receptor in patients with lupus nephritis: relationship between receptor levels in mononuclear leukocytes and effect of glucocorticoid therapy. J Rheumatol. 1992; 19: 878- 883.

[56] Goodman RH , Smolik S . CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14 (13): 1553- 1577.

RIGHTS & PERMISSIONS

The Author(s). Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.